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Behavioural and molecular endophenotypes in psychotic
disorders reveal heritable abnormalities in glutamatergic
neurotransmission
L Scoriels1,2, RM Salek3,4, E Goodby1, D Grainger5, AM Dean1, JA West3, JL Grifﬁn3, J Suckling1, PJ Nathan1,6, BR Lennox1, GK Murray1,7,
ET Bullmore1,7,8 and PB Jones1,7
Psychotic disorders such as schizophrenia are biologically complex and carry huge population morbidity due to their prevalence,
persistence and associated disability. Deﬁned by features such as delusions and hallucinations, they involve cognitive dysfunction
and neurotransmitter dysregulations that appear mostly to involve the dopaminergic and glutamatergic systems. A number of
genetic and environmental factors are associated with these disorders but it has been difﬁcult to identify the biological pathways
underlying the principal symptoms. The endophenotype concept of stable, heritable traits that form a mechanistic link between
genes and an overt expression of the disorder has potential to reduce the complexity of psychiatric phenotypes. In this study, we
used a genetically sensitive design with individuals with a ﬁrst episode of psychosis, their non-affected ﬁrst-degree relatives and
non-related healthy controls. Metabolomic analysis was combined with neurocognitive assessment to identify multilevel
endophenotypic patterns: one concerned reaction times during the performance of cognitive and emotional tests that have
previously been associated with the glutamate neurotransmission system, the other involved metabolites involved directly and
indirectly in the co-activation of the N-methyl-D-aspartate receptor, a major receptor of the glutamate system. These cognitive and
metabolic endophenotypes may comprise a single construct, such that genetically mediated dysfunction in the glutamate system
may be responsible for delays in response to cognitive and emotional functions in psychotic disorders. This focus on glutamatergic
neurotransmission should guide drug discovery and experimental medicine programmes in schizophrenia and related disorders.
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INTRODUCTION
Psychotic disorders present a variety of debilitating cognitive and
emotional impairments. Problems with memory, cognitive ﬂex-
ibility, ability to plan and emotional perception1–3 often lead to
difﬁculties in social integration and stable employment; this is why
psychotic disorders rank number one in global costs for brain
disorders in Europe.4 Memory, executive function and emotional
perception impairments are inherent to the disease, often appear
before its onset, and may be present in people genetically related
to patients.5,6 These characteristics deﬁne what is commonly
known as an endophenotype and suggest a genetic predisposi-
tion to these symptoms. Multiple genetic studies have been
performed to uncover the causes of cognitive symptoms in
psychotic disorders, but because of its biological complexity and
pronounced heterogeneity, it has been difﬁcult to associate
cognitive symptoms to any single gene. The endophenotype
concept simpliﬁes this relationship. Cognitive and emotional
endophenotypes are the manifestations of abnormalities in
neurophysiological systems that are closer to the molecular and
genetic mechanisms of the disorder.
Magnetic resonance spectroscopy has shown distortions in
speciﬁc metabolite levels, such as phosphocreatine, choline or
glutamine, in different parts of the brain at the ﬁrst episode and
chronic schizophrenia. These distortions were shown to be directly
linked to neurocognitive deﬁcits of the disease.7–9 Metabolic
dysregulations do not appear to be solely attributable to
antipsychotic treatment and lifestyle but also seem to be inherent
biological dysfunctions speciﬁc of the disorder7–15 as suggested
by studies in relatives of patients with schizophrenia.16–18
Metabolomics is a relatively new technique that analyses the
complete collection of metabolites produced by an organism and
gives a more dynamic proﬁle compared with proteomics or
genomics.19 The technique has been applied to white and grey
matter postmortem brain tissue in schizophrenia and showed an
imbalance in metabolites involved in both glucose and oxidative
stress functions in mitochondria in individuals with
schizophrenia.20 The investigators found the same dysregulations
in the cerebrospinal ﬂuid of prodromal and early psychosis
patients21,22 and in peripheral blood of patients with
schizophrenia,23 suggesting that the analysis of non-cerebral
biological samples can inform brain states related to schizo-
phrenia. However, this technique has not been applied to relatives
of patients with psychotic disorders, or to underlying psycho-
pathological domains. It is not known whether the global
metabolic proﬁle in psychosis can be considered as an
endophenotype.
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In this study, we investigated whether multiple hierarchical
endophenotypes link genotype, psychopathology and clinical
phenotype, a concept put forward by Craddock and Owen.24 First,
we assessed whether cognitive and emotional performance and
reaction time would show an endophenotypic pattern, which
would discriminate individuals with a ﬁrst episode of psychosis
(named hereafter probands) from their ﬁrst-degree relatives
(relatives) and from healthy unrelated controls (controls). First-
degree relatives share around 50% of their genetic background
with probands and often have increased risk for the disorder.
Second, we analysed metabolic proﬁles in peripheral blood from
these three groups to determine whether catecholamine and
glutamatergic metabolites also showed endophenotypic patterns.
Finally, we investigated the associations between any such
endophenotypes.
Our overall strategy indicated that we would ﬁnd deﬁcits in
performance and reaction time in cognitive and emotional tests in
probands compared with unrelated controls, with relatives
occupying an intermediate position. We also hypothesised that
probands, and to a lesser degree their relatives, would present an
over-expression of metabolites involved in the dopaminergic
neurotransmission system and a hypo-expression of metabolites
involved in the glutamatergic neurotransmission system. These
represent the two leading neurotransmitter hypotheses of
schizophrenia pathophysiology and are supported by recent
molecular genetic ﬁndings.25 Finally, we hypothesised that the
endophenotypes in behavioural tests would be associated with an
imbalance in metabolic proﬁles.
We analysed only those cognitive and emotional variables
relevant to our hypothesis to reduce the risk of type I error.
Furthermore, we used principal component analysis (PCA) to
reduce the number and complexity of the metabolic variables.
MATERIALS AND METHODS
Study design and sample
The study was a genetically sensitive trio-design of 34 probands with ﬁrst
episode psychosis (FEP), 34 ﬁrst-degree relatives and 35 unrelated healthy
controls. FEP probands were recruited from CAMEO, the early intervention
service for psychosis in Cambridgeshire and Peterborough in the United
Kingdom (www.cameo.nhs.uk)26–29 and from similar services in London,
Suffolk and Nottinghamshire (the study was approved by the Research
Ethics Committee in Cambridgeshire, London (06/Q0108/129), Suffolk (07/
Q0102/26) and Nottinghamshire (AMH/31/01/08)). Probands were included
according to DSM-IV criteria for any psychotic disorder without identiﬁable
medical cause30 and had to be within a year of presenting with their ﬁrst
episode. Probands’ ﬁrst-degree relatives included siblings and parents. We
included only relatives without psychotic disorder according to DSM-IV.
Healthy unrelated control subjects had no history of psychiatric disorder
themselves or in their family. Participants were excluded if they had any
history of head injury or major learning disability or if they scored
positively for standard psychostimulant substances tested in urine samples
or had a blood alcohol level above 80mg l− 1. Healthy controls were
excluded if they had taken psychoactive drugs within 2 weeks before the
assessment. Most probands with FEP were taking antipsychotic medication
and were asked to continue their treatment for ethical and practical
reasons. All the participants provided written informed consent before the
study and gave a blood sample and performed a battery of cognitive and
emotional tasks during the study. Two probands were excluded for
presence of drugs in a urine test and brain abnormality, respectively.
Serum preparation
Serum samples were collected and stored at − 20 °C. None of the samples
underwent more than three freeze–thaw cycles before acquisition by
nuclear magnetic resonance (NMR) spectroscopy or liquid chromatography
coupled with mass spectroscopy. All the experiments were performed
under blind and randomised conditions.
Behavioural analysis
A number of cognitive and emotional domains were assessed. We
measured working memory using the letter version of the n-back task,
which displays a sequence of different letters and requires participants to
press a button whenever they see the same letter as the one seen n-back.
Planning abilities were tested with the computerised CANTAB Stockings of
Cambridge task, which requires participants to reorganise patterns
following a model and a set of rules. Emotion recognition was assessed
with the emotion intensity recognition test, which displayed a sequence of
faces showing one of the six emotions: happiness, surprise, sadness, fear,
disgust and anger. Participants were asked to rate how intense a given
facial emotion was. Processing speed of the brain was assessed with the
reaction time task, which required participants to press a button as fast as
they could when they saw a ball appear in the screen. These tests have
been described elsewhere.27,31–33 One-way or multivariate analysis of
variance (ANOVA and MANOVA, respectively) models were used. Normality
and homogeneity of data distribution was conﬁrmed using the Shapiro–
Wilk and Levine tests. Where appropriate transformations did not result in
normal distributions, the non-parametric Kruskal–Wallis test was used. Post
hoc two-tailed t-tests were applied on the measures that led to signiﬁcant
results in the ANOVA or MANOVA. Data were analysed with SPSS software
version 15 (Cambridge, UK).
1H-NMR spectroscopy acquisition, processing and data reduction
A total 150–200 μl of serum was diluted with 350 μl of 0.9% sodium
chloride in water with 10% deuterium for 1H-NMR spectroscopic analysis.
1H-NMR spectra data sets were collected using a Bruker (Cambridge, UK)
Avance-III 600 MHz magnet at a nominal proton frequency of 600.13MHz
at an ambient temperature of 310 K, using Bruker TopSpin (version 2.1.3)
software for both acquisition and data processing. A standard Carr–
Purcell–Meiboom–Gill34 pulse sequence was used for one-dimensional
data acquisition, with pre-saturation to allow elimination of the solvent
signals during the relaxation delay of 1.5 s. An electromagnetic pulse
perpendicular (90°) to the main magnetic ﬁeld was induced to the sample
for 90 μs and then a sequence of 63 other perpendicular electromagnetic
pulses (180°) with opposite directions was applied with intervals of 1.2 s.
Sixty-four scans were collected in total with 32 768 data points in a sweep
width of 8389.3 Hz. The free induction decay was therefore 1.95 s. For data
processing, the free induction decays were multiplied by a 0.3 Hz
exponential weighting function and zero-ﬁlled to 65 536 data points
before Fourier transformation. Corrections for distortions of the spectra
were applied taking lactate (CH3 = δ 1.33) as a reference. The region
around the water peak (δ 5.2− δ 4.4) was excluded, as this signal
dominates the spectrum despite solvent suppression due to the
abundance of the solvent. The resulting NMR spectra were data reduced
(binned) in the region δ 10.0−δ 0.0 in integral segments of equal length (δ
0.01) using the Bruker AMIX software (version 3.8.3). Normalisation to total
spectral area was performed by calculating the relative contribution of
each bin as a fraction of the total spectral area. Peak alignment and
positive and negative control data were checked for the normalised data.
Liquid chromatography-mass spectrometry
Hundred microlitres of serum was thoroughly dried under nitrogen and
derivatised with 400 μl of 3 M HCl in BuOH for 15min at 65 °C. After further
drying, the sample was reconstituted in 9:1 0.1% formic acid in water/
acetonitrile and sonicated to ensure solvation of the amino-acid
derivatives. Samples were analysed using a Quattro Premier XE MS
coupled to an Acquity UPLC system (Waters, Manchester, UK). The strong
mobile phase used for analysis was acetonitrile and the weak mobile phase
was 0.1% formic acid in water. The analytical UPLC gradient used a HSS T3
column (100mm×2.1 mm, 1.7 μm) from Waters with 5% acetonitrile in
0.1% formic acid at 0 min followed by a linear gradient to 40% acetonitrile
after 7 min followed by re-equilibration for 3 min. The total run time was
10min and the ﬂow rate was 0.3 ml min− 1 with an injection volume of 3 μl.
The mass spectrometry parameters were: dwell time 0.02 s, source
temperature 150 °C, desolvation temperature 350 °C, capillary voltage 3.
5 kV and 700 l h− 1 of desolvation gas, all other parameters were
compound speciﬁc.
Metabolomic analysis
Resulting NMR data were analysed with the SIMCA-P+ software (version
13). Data with no variance were eliminated and the remaining data were
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winsorised35 to ± 3 s.d. to moderate the impact of outliers. Pareto scaling36
was selected for the models shown here following pragmatic comparison
of models built on the unscaled and unit variance scaled data. The NMR
spectra were analysed with PCA and partial least square (PLS) models,
which are two projection methods that use mathematical algorithms to
reduce multivariate data into a few principal components (PCs) that
describe the maximum variation within the data. PCA is deﬁned as an
orthogonal linear transformation that reduces multidimensional data to a
new linear coordinate system such that the greatest variance by any
projection of the predicted variables comes to lay on the ﬁrst coordinate,
called the ﬁrst PC, the second greatest variance on the second coordinate
and so on. PCA is independent of observable variables and is mostly used
as a tool in exploratory data analysis and for making predictive models. PLS
is deﬁned as a linear construct that projects the predicted and observed
variables to a new space, specifying the linear relationship between the
two observable variables. PLS also produces PCs, which are calculated from
the greatest covariance of the predicted and observed variables, and not
only the predicted variables, as for PCA. PLS is used as a classiﬁcation tool
for identifying the differences between groups of samples. Here, a PCA was
used to reduce the NMR spectrum data into a few PCs that described the
maximum variation within the data independently of psychotic hereditary
group category. PLS was used with determined group category and
enabled the identiﬁcation of variables related to groups of observation (or
classiﬁcations). The extent to which PCs from PCA and PLS segregated
probands, relatives and controls was tested by comparing the observed
distribution of peaks in these three groups with an expected random
distribution using χ2.
A global model was obtained from the PCA and PLS, and cross-
validation was applied to test its signiﬁcance. Cross-validation consisted in
repeating the same PCA and PLS analyses as previously, with only 75% of
randomly selected samples from each group category. This enabled the
construction of a model that was used to predict how the remaining 25%
hold-out samples would segregate in the established class models on the
basis of their best ﬁt and goodness of prediction to the model. For each
subject in the validation set, a predicted Y value (Y’) was computed by
applying the loadings from the PLS model to the measured X variables for
these subjects. To avoid scaling artefacts, and to minimise the impact of
arbitrary class cut-offs, predicted class membership was assigned by
allocating class 1 membership to the lowest tertile of the Y’ values in the
hold-out set, class 2 membership to the middle tertile and class 3
membership to the upper tertile. External prediction of the model was
performed using χ2 that compared each predicted group category to the
actual group category. A parallel graphical analysis was performed on
calculated mean differences between groups. Candidate NMR chemical
shift regions were isolated for any difference between these calculated
mean differences superior to two standard errors (s.e.). Metabolic
candidate compounds were selected using the chemical shift regions
from graphical and the PC that showed the greatest variance between all
the three groups, and subsequently identiﬁed using the Human
Metabolome Database (www.hmdb.ca)37 and Chenomx NMR Suite
(Chenomx version 7.6). Liquid chromatography coupled with mass
spectroscopy was performed using the same serum samples and data
were analysed using one-way ANOVA statistical technique.
RESULTS
Demographics
Demographic analysis showed no difference between groups for
age, ethnicity or premorbid IQ. There was a signiﬁcant difference
in the gender ratio between the three groups, due to parents in
the relative group being predominantly represented by mothers
(Table 1), whereas the proband group was most represented by
men. Hence, further statistical analyses included gender as a
covariate in all parametric analyses.
Cognitive and emotional endophenotypes
The participants performed a selection of tests of memory,
executive and emotional functions. The performance of the n-back
task, a test of working memory, showed that the three groups
differed statistically signiﬁcantly for reaction time (χ2 = 7.04,
P= 0.03, Kruskall–Wallis test) with probands being the slowest,
followed by their relatives; controls were the fastest (Figure 1a).
There was a difference for accuracy on the more difﬁcult (3-back)
working memory task that reached statistical trend levels
(χ2 = 5.01, P= 0.08); probands showed the worst performance,
followed by their relatives; controls showed the best performance.
The three groups did not differ for the control task (‘look for X’)
and the easy (1-back) working memory task (Figure 1a). Executive
function was assessed with the CANTAB Stockings of Cambridge
test that measures cognitive planning abilities. Probands, their
relatives and controls differed signiﬁcantly for their planning
reaction time (F(2,91) = 5.16, P= 0.008, Figure 1b). Post hoc t-tests
showed that probands and relatives took signiﬁcantly more time
to plan moves compared with controls (t(30) = 2.22, P= 0.03 and t
(30) = 3.00, P= 0.004, respectively). The three groups did not differ
in the number of problems solved in minimum moves.
The assessment of emotional processing with the emotion
intensity recognition task showed differences between the three
groups for the reaction time of all emotions (MANOVA, all F(2,96)
43.50 and Po0.05, Figure 1c). Post hoc t-tests showed that
probands were performing signiﬁcantly slower compared with
controls for all reaction times of emotion intensity recognition task
(all t(30)42.5, Po0.05). Relatives showed signiﬁcant increase in
reaction time compared with controls for fear (t(30) = 2.68, P= 0.01),
sadness (t(30) = 2.15, P= 0.04) and happiness (t(30) = 2.43, P= 0.02).
There was a signiﬁcant difference in reaction time for surprise
intensity recognition between probands and relatives (t(30) = 2.33,
P= 0.02, Figure 1c). The three groups did not differ signiﬁcantly for
accuracy in the identiﬁcation of emotional intensity.
Tests of purely motoric functions, the one- and ﬁve-choice
reaction time tests, showed no statistical differences between the
three groups (Figure 1d).
Metabolic endophenotypes
We used proton NMR spectroscopy (1H-NMR) to investigate
whether potential endophenotypes were related to metabolic
dysfunction. The initial NMR data set was composed of 1026 bin
separated regions for each participant, reduced to 365 after
winsorisation and elimination of data with no variance (small
signal-to-noise ratio). The data set was analysed using multivariate
approaches with algorithms and projection-based methods aimed
at reducing the dimensionality of the data. PCA, an unsupervised
method (independent of the group classiﬁcation) and partial least
square discrimination analysis (PLS-DA), a supervised approach
(dependent on the group classiﬁcation) were used to analyse the
data set. PCA allows analysing the NMR-derived metabolic proﬁles
Table 1. Participants demographic information
Probands n=34 Relatives n= 34 Controls n=35 P-value
Age (mean years± standard error) 23± 1 31± 2 27± 2 0.27
Gender (men, women) 24, 10 14, 20 21, 12 0.04
Ethnicity (white European, others) 30, 4 30, 4 33, 2 0.91
Estimated verbal IQ (National Adult Reading Test) (mean score± standard error) 111± 1 110± 1 108± 1 0.24
Body mass index (mean score± standard error) 25± 1 24± 1 25± 1 0.20
Abbreviation: IQ, intelligence quotient. Bold values are statistically signiﬁcant.
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for bin regions representing chemical peaks of organic com-
pounds. Both PCA and PLS methods facilitate the identiﬁcation of
candidate compounds, levels of which may vary between the
three groups (probands, relatives and controls) according to
psychosis hereditary association.
A PCA model was built using 10 components, which explained
~ 70% of the variance (R2(X) = 0.69) and had a predictability of 53%
(Q2(X) = 0.53). Analysis of the PCs by group classiﬁcation showed
that the seventh component (PCA-PC7) was responsible for the
best segregation of bin regions between FEP probands, their ﬁrst-
degree relatives and healthy controls (χ2 = 16.92, P= 0.0002). The
third component (PCA-PC3) also segregated bin regions differen-
tially, depending on the group classiﬁcation, although more
moderately (χ2 = 6.83, P= 0.03). No other PC showed statistically
signiﬁcant differences between the groups (P40.05). The
segregation was such that metabolic proﬁles from probands in
PCA-PC7 were in one extremity of the plot and controls on the
other extremity, with relatives half way through probands and
controls metabolic proﬁles.
A global PLS model (PLSg) was ﬁrst built with all the data. Data
auto-ﬁtted a PLS model with two components, with a predicted
best ﬁt of R2(X) = 0.38. Analysis of the bin regions by group
classiﬁcation showed that the second PC (PLSg-PC2) was
responsible for the best statistically signiﬁcant segregation of
bin regions distribution between probands, relatives and controls
(χ2 = 19.06, P= 0.00007) and the pattern was the same as the one
seen in the PCA model. The ﬁrst component (PLSg-PC1) also
signiﬁcantly segregated bin regions between groups, but the
effect was smaller than for PLSg-PC2 (χ2 = 9.62, P= 0.01, Figure 2).
A new PLS model was built for external validation (PLSev) with
75% of randomly selected participant samples from each group.
PLSev was optimised for a model containing 9 PCs, which showed
similar patterns of segregation between metabolic bin regions
from probands, their ﬁrst-degree relatives and controls, with
relatives in an intermediate position (PLSev-PC2 (χ2 = 23.44,
P= 0.000008), PLSev-PC3 (χ2 = 18.96, P= 0.00008), PLSev-PC1
(χ2 = 8.89, P= 0.01)). External validation with the remaining 25%
of the data showed the same pattern but did not reach statistical
signiﬁcance (P= 0.24).
Since the PCA model suggests an endophenotypic separation by
group classiﬁcation in an unsupervised manner (that is, that does
not consider the groups classiﬁcation when calculating the PCs),
Figure 1. Cognitive, emotional and motoric reaction time responses. (a) Reaction time on the n-back task showed that probands (red lines,
n= 32), relatives (green lines, n= 34) and controls (blue lines, n= 33) were slower according to task difﬁculty. The three groups did not present
any differences in reaction time for the ‘look for X’ and the 1-back tasks (P40.05), but they did for the 3-back task (Po0.05), with probands
being signiﬁcantly slower than controls, and relatives having a pattern in between the two. (b) Reaction time on the CANTAB Stockings of
Cambridge (SOC). Probands (n= 32) and relatives (n= 34) were signiﬁcantly slower compared with controls (n= 32) (Po0.01). (c) Latency of
each emotion from the Emotion Intensity Recognition Test (EIRT). Latencies in the EIRT task showed that probands were slower at recognising
intensities for all emotional faces compared with controls (Po0.05). They were also slower than their relatives to recognise surprise. Relatives,
in turn, were signiﬁcantly slower than controls to recognise fear, sadness and happiness facial intensities (Po0.05). (d) Latency on the CANTAB
one- and ﬁve-choice reaction time. There were no statistical differences between the three groups (P40.05). Error bars represent s.e.m.
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this model was used to select endophenotypic metabolic
candidates. All bin regions found to be in excess of expected
frequency from a Gaussian distribution in PC7 were identiﬁed.
Differences in distribution calculated between probands and their
relatives, probands and controls and relatives and controls were
analysed graphically in an eigen-spectrum (Supplementary Table 1).
Identiﬁcation of metabolites converges on the glutamatergic
biological pathway
The Human Metabolome Database and Chenomx NMR Suite
(Chenomx version 7.6) were used to search and identify the
chemical shifts found both from PCA-PC7 and the graphical
analyses. Five metabolic candidates were annotated on the basis
of the NMR chemical shift regions that were over-expressed
in probands: α-aminocyclo-propanecarboxylate (ACPC), lactate,
acetate, 1-hydroxyisobutyrate and octane. ACPC is a partial
agonist/antagonist of the glycine cotransmitter site of the
N-methyl-D-aspartate (NMDA) receptor.38 L-lactic and acetic acid
are components of the glycolytic metabolic pathway.39 However,
no metabolic functions have yet been assigned to 1-hydroxyiso-
butyrate and octane. The bin regions that were under-expressed
in probands were much more abundant and led to 10 metabolic
candidates: D-serine, glycine, betaine, guanidoacetate, dimethyl-
sulﬁde, phosphocreatine, pyruvate, 1,9-dimethyluric acid, tri-
methylamine oxide and diethanolamine (Table 2).
Glycine and D-serine are both co-activators of the glycine
cotransmitter site of the NMDA receptor.40 Betaine, guanidoace-
tate, dimethylsulﬁde, phosphocreatine and pyruvate are metabo-
lites involved in the anabolism and catabolism of glycine and
serine via the methionine to cysteine metabolism in astrocytes
(cells that provide nutrients, neurotransmitters and co-activators
to synapses).41 Trimethylamine oxide is also likely to be related to
this metabolism, as it has been shown that betaine can produce it
in two chemical reactions steps in marine animals;42 however,
data in humans are not available. 1,9-Dimethyluric acid is involved
in the metabolism of urine, purines and caffeine,43 but no
connections with metabolic dysfunctions in psychosis have yet
been reported. Diethanolamine is an exobiotic compound that
can be metabolised by biosynthetic routes common to ethano-
lamine, which again is involved in glycine and serine metabolism,
albeit more remotely.44
Liquid chromatography coupled with mass spectroscopy was
performed to verify the identity of the main candidate metabolites
from the NMR, that is, metabolites involved in the glutamatergic
system. One-way ANOVA did not show statistically signiﬁcant
differences between groups for levels of glycine (F = 0.76, P= 0.47),
serine (F = 1.26, P= 0.29), ACPC (F = 0.10, P= 0.91) or betaine
(F = 1.30, P= 0.28).
Two endophenotypes but a single construct?
We performed two-tailed Pearson correlations between the scores
obtained in cognitive and emotional reaction time tasks and the
intensity of the NMR chemical shift regions from the candidate
metabolites that segregated the three groups to the greatest
degree. Only three negative correlations were found between the
bin region corresponding to dimethylsulﬁde (2.095) and the
reaction time to identify sad, surprised and happy faces intensities
(r=− 0.21, P= 0.04 for the three emotion intensities).
DISCUSSION
This study shows linearity in reaction time responses related to
cognition and emotion in probands, relatives and controls that are
consistent with endophenotypic characteristics. Probands, and to
a lesser extent, relatives respond to cognitive and emotional tests
more slowly than healthy, unrelated controls. Slower reaction time
may have a deleterious impact on subjects’ day-to-day function
despite having little effect on performance in the controlled
context of the experimental paradigm. Indeed, it may well be that
patients develop performance impairments as a consequence of
increased latencies in several domains of their lives, in situations
dependent upon optimal cognitive and emotional abilities.
Linearity is also observed in the distribution of the metabolic
proﬁle of the three group categories. Probands show a distribution
of chemical peaks in one extreme of the PLS score plot, whereas
controls show a distribution that spreads in the opposite direction.
The chemical peaks from probands’ ﬁrst-degree relatives overlap
with the two other groups’ distributions. These variations in
chemical shift distribution between the three groups appeared to
be mostly due to changes in the glutamatergic neurotransmission
system in general, and the anabolism and catabolism of serine
and glycine, in particular.
In the normal glutamatergic synapse system, vessels supply
astrocytes surrounding the synapse with glycine and L-serine.
These are then metabolised and glycine and D-serine are released
in the inter-synaptic space.40 When the pre-synaptic neuron
releases glutamate, it binds to NMDA and AMPA receptors. AMPA
receptors are activated and create a depolarisation in the post-
synaptic cell. This depolarisation, combined with glutamate and
glycine/D-serine binding to NMDA receptors45 induces a long-term
potentiation in the post-synaptic cell, which consolidates neuronal
signalling.40 The signalling ends when neurons and astrocytes re-
uptake neurotransmitters and co-activators. Astrocytes are efﬁ-
cient in the re-uptake of these compounds, which enter the cell
metabolism and are recycled for future signalling (Figure 3a). The
metabolic candidate compounds found in this study suggest that
the metabolism involved in the synthesis or transport of glycine
and D-serine may be down-regulated, inducing a reduction or a
lack of glycine and D-serine in the glutamate neuron synapse
interspace. As a consequence, ACPC, which appears to be overly
abundant, binds the NMDA co-activator site and because of its
reduced afﬁnity for the site,46 ACPC may actually act as an
antagonist of the NMDA receptor,47 causing a reduced activity or a
failure to induce a long-term potentiation in the post-synaptic cell
(Figure 3b).
Figure 2. Groups distribution of nuclear magnetic resonance (NMR)
chemical shift regions in components from the global partial least
square (PLS) model. Red circles represent NMR chemical shift
distribution in probands (n= 34), green circles NMR chemical shift
distribution in relatives (n= 33) and blue circles NMR chemical shift
distribution in controls (n= 35). Component 2 shows a signiﬁcant
split between probands, relatives and controls (χ2= 19.05,
P= 0.00007). Component 1 also shows an effect of group in the
segregation of peaks to a more moderate level (χ2= 9.62, P= 0.01).
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The under-expression of glycine and D-serine in patients with a
ﬁrst episode of psychosis is consistent with a hypofunction of the
NMDA receptor, which is one of the theories explored to explain
the neurophysiopathology of schizophrenia,48 and supports
studies that show the efﬁciency of glycine treatment in negative
and other psychiatric symptoms in schizophrenia.49 Importantly,
this study provides strong, though not yet deﬁnitive, evidence
that the metabolic dysfunctions observed in probands are not
only limited to the NMDA receptor co-activators themselves, but
to metabolic pathways involving their anabolism and catabolism
via the methionine and cysteine system. These dysfunctions follow
an endophenotypic pattern, as relatives show imbalances that are
intermediate between probands and controls.
It is known that the NMDA receptor is involved in several
cognitive functions, and in memory in particular.50 Thus, the
question that followed our investigation is whether the endophe-
notypic patterns of imbalances observed in metabolites were at all
associated with the endophenotypic patterns found in cognitive
and emotional reaction times in FEP probands. The correlations
between the two endophenotypes were weak, probably because
of the mechanistic distance between them. However, the
literature suggests that hypofunction of the NMDA receptor
induces a slowing of reaction time in tasks related to cognition but
not motor functions.51,52 This is exactly what our data show,
although replication is needed with a larger sample size to specify
the effect more precisely. Reaction times related to memory,
cognitive ﬂexibility and emotion recognition were increased in
probands and to a lesser extent, in relatives compared with
controls; however, reaction times that did not involve cognitive or
emotional functions, did not show this pattern, suggesting that
the endophenotypic imbalance found in the glutamatergic system
may be causing the impairments in reaction times related
to cognition and emotion functions, albeit remotely. We believe
this is the ﬁrst time that endophenotypes at different levels,
psychological and molecular, appear to form a single construct.
There are caveats to this study. First, the sample size for this
study was at the lower limit for a differential detection of
metabolites between the three groups. Nevertheless, if the peaks
identiﬁed in the metabolomics analysis had been statistical quirks
due to the small sample size, identiﬁed only as a result of model
over-ﬁtting, then there is little chance they would have, again by
chance, been associated with a common metabolic pathway, that
is, the NMDA receptor co-activators metabolism. The difﬁculty in
identifying these individual metabolites with liquid chromatogra-
phy coupled with mass spectroscopy demonstrates discrepancies
between the two techniques that have also been shown in other
studies53 and points out the technical and statistical challenges
that are yet to be overcome in terms of ﬁnding biological markers
in psychiatric disorders. For this reason, increasingly formalised
‘pathway analysis’ has gained in popularity as an approach to
multivariate modelling of metabolomic data sets and this kind of
analysis provides robust validation of the multivariate modelling. It
seems very likely that the metabolic imbalance leading to
decreased levels of NMDA receptor co-activators is an important
pathway predisposing to FEP, and future studies should focus on
testing this proposition.
Second, we need to consider the possibility that effects of
antipsychotic drug treatment may have affected our results. We
think the endophenotypic pattern is unlikely to have been caused
in this way because drug treatment in probands with psychosis
would not explain the intermediate position of unaffected
relatives between probands and healthy unrelated controls.
Nevertheless, the impact of treatment on the metabolic signature
identiﬁed cannot be completely excluded. Indeed, animal studies
have shown that typical (haloperidol) and atypical (clozapine)
antipsychotics modulate NMDA receptor function.54 However, the
protective effects of these agents against NMDA receptor
antagonists (MK-801), which produce psychosis-like symptoms,
suggest that the antipsychotic medication induce NMDA receptors
and do not down-regulate them.55 Similarly, clozapine, like D-
serine, enhances social memory in rats,56 suggesting that
clozapine is likely to increase levels of D-serine rather than reduce
it. Thus, it is highly improbable that the metabolic dysfunction
presented in this study is related to medication intake, and the
proposition that the only effective treatments for psychosis
increase NMDA receptors only underlines further the plausibility
of a molecular signature of FEP involving loss of NMDA receptor
co-activators. Furthermore, NMR signals from medication-related
metabolites were analysed and compared against the list of
metabolic candidates that were revealed from the metabolomic
analysis. Medication did not appear to have ‘contaminated’ the
results, as the candidate metabolites presented here were linked
to different compounds than those present in the products of
antipsychotic drugs.
Despite these caveats, it was striking that the cognitive and
emotional impairments in psychosis and the under-expression of
NMDA receptor co-activators all followed an endophenotypic
pattern. This further supports the model of hypofunction in this
receptor as a key step in the pathogenesis of psychosis.57 The link
between NMDA receptors and both immunologic58 and acceler-
ated ageing processes59 implicated in psychosis. The immune
Table 2. Candidate metabolites over- and under-expressed in probands
Candidate metabolic compounds with
under-expressed peaks
Candidate metabolic compounds with over-
expressed peaks
Metabolic function
Serine
Glycine
α− aminocyclo-propanecarboxylate Metabolites involved in the activation of the NMDA receptor
Guanidoacetate
Dimethylsulﬁde
Phosphocreatine
Betaine
Diethanolamine
Trimethylamine oxide
Metabolites involved in the anabolism and catabolism of
glycine and serine via the methionine to cysteine
metabolism
Pyruvate Lactate
Acetate
Metabolites involved in the oxygenation system
1,9 Dimethylurate Metabolite involved in the urine, purine and caffeine
metabolism
Hydroxyisobutyrate
Octane
Compounds related to petrol
Abbreviation: NMDA, N-methyl-D-aspartate. Metabolic candidate compounds directly involved in the NMDA glycine cotransmitter site are in bold. Metabolic
candidate compounds indirectly involved in the NMDA glycine cotransmitter site are in italics.
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Figure 3. Role of the metabolites found in the metabolomics technique. (a) Normal glutamate neuron synapse. Glutamate from the pre-
synaptic cell binds the post-synaptic AMPA and NMDA receptors. Na+ and K+ ions enter the post-synaptic cell, via AMPA receptors, creating a
depolarisation. Then, NMDA receptors that have bound glutamate and the co-activator glycine or D-serine, which comes from the surrounding
astrocytes, free their channel from Mg2+, allowing Na+ and Ca2+ to enter the post-synaptic cell, which creates a long-term potentiation. After
the signal is transmitted, glutamate is re-uptaken by excitatory amino acid transporter (EAAT) located in the pre-synaptic cell and astrocytes.
Glutamate that enters the astrocytes is transformed in glutamine by the glutamine synthase and is transported to the pre-synaptic cell via
alanine serine cysteine transporter (ASCT) or speciﬁc neutral amino acid transporter (SNAT) and re-synthesised in glutamate because of the
glutaminase enzyme. Glycine can come from the vascular system via glycine transporters (GLY-T1) or SNAT, or from its metabolism, from
transformation of L-serine with the serine hydroxyl-methyl transferase (SHMT) or from sarcosine that involves methylation and demethylation
processes. Glycine is released to the synapse interspace via GLY-T1. The D-serine is synthesised from L-serine with the racemase enzyme and
released to the synapse interspace by the D-serine transporter (D-SERT). The L-serine can be brought by the vascular system via the L-serine
transporter (L-SERT) or be synthesised from glycine with the SHMT. The D-serine can also be synthesised from pyruvate via the D-amino acid
oxidase (DAO). The NMDA glycine/D-serine co-activation sites can also bind to a less extent α-amino cyclopropane carboxylic acid (ACPC),
which is a partial agonist of this site. (b) Metabolic dysfunction that may occur in the glutamate synapse in ﬁrst episode psychosis. Metabolism
involved in the synthesis or transport of glycine and D-serine appears to be down-regulated, inducing a reduction or a lack of glycine and D-
serine in the synapse interspace. As a consequence, ACPC can bind the NMDA co-activator site, but because of its reduced afﬁnity, the NMDA
receptor has a reduced activity or fails to induce a long-term potentiation in the post-synaptic cell.
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system is actually highly involved in the pathophysiology of
schizophrenia and also deserves further attention.60,61
The endophenotype concept gives the opportunity to
overcome current technological issues and provides answers
concerning the biological mechanisms involved in the etiophysio-
pathology of psychotic disorders. Thus, in light of these results, we
suggest that new neuropsychological and neuropharmaco-
logical treatments targeting cognitive and emotional impairments
in psychosis should be developed in the context of abnormalities
in the glutamatergic neuronal system.
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